The global community acquired methicillin resistant market is anticipated to grow at a significant CAGR during the forecast period (2021-2027). A community-acquired infection is an infection that was present or incubating at the time of admission and was not caused by an organism acquired during previous health care. Methicillin-resistant Staphylococcus aureus (MRSA) has emerged as a key pathogen among hospitalized patients. According to the United States Department of Health (USDoH), 20% of the global population is always colonized with Staphylococcus aureus. Being a facultative anaerobe, it can cause respiratory diseases, skin illness, and food poisoning. As per the National Center for Biotechnology Information (NCBI), two novel antimicrobial agents that include quinupristin/ dalfopristin, and linezolid, have emerged as approved therapeutic options for vancomycin-resistant Enterococcus faecium on the basis of in vitro susceptibility and clinical efficacy from multicentre, pharmaceutical company-sponsored clinical trials. 

According to the Health Research Funding Organization, nearly 19,000 mortalities are registered globally due to Staph infection every year. According to Centre of Disease Control and Prevention (CDC), there were 13 cases in 4 states of US, during 2002-2013. In due course of time, the species of Staphylococcus aureus have developed resistance to many of the antimicrobial drugs. For instance, MRSA, a class of Staphylococcus aureus which is resistant to Methicillin. Other than the majorly known Staph infection, it is also the common contributing agent for illnesses such as boils, impetigo, pimples, abscesses, and certain serious diseases such as pneumonia, meningitis, osteomyelitis, sepsis, and others. Thus, to treat such illnesses, the global community acquired methicillin resistant staphylococcus aureus drug market is likely to grow during the forecast period.

Market Coverage

• The market number available for – 2020-2027

• Base year- 2020

• Forecast period- 2021-2027

• Segment Covered- 

o By Product

o By Application 

• Regions covered-

o North America

o Europe

o Asia-Pacific

o Rest of the World

• Competitive Landscape:  Allergan plc, and Merck & Co., Inc., among others.

Key questions addressed by the report

• What is the market growth rate?

• Which segment and region dominate the market in the base year?

• Which segment and region will project the fastest growth in the market?

• How COVID-19 impacted the market?

o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

• Who is the leader in the market?

• How are players addressing challenges to sustain growth?

• Where is the investment opportunity?

Global Community Acquired Methicillin Resistant Staphylococcus Aureus Drug Market Report by Segment

By Product

• VAL-301

• GLPG-1492

• Solithromycin

• Acorafloxacin Hydrochloride

By Application

• Hospital

• Clinic

• Others

Global Community Acquired Methicillin Resistant Staphylococcus Aureus Drug Market Report by Region

North America       

• US

• Canada

Europe

• Germany

• UK

• France

• Spain

• Italy

• Rest of Europe

Asia-Pacific    

• China

• Japan

• India

• Rest of Asia-Pacific

Rest of the World

• Latin America

• Middle East and Africa